Reasons-stratified treatment retention after JAK inhibitor discontinuation in rheumatoid arthritis: the ANSWER cohort study

Clicks: 17
ID: 333076
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #205 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective To compare the retention and disease activity trajectories of subsequent biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) after Janus kinase inhibitor (JAKi) discontinuation in patients with rheumatoid arthritis (RA). Methods We analysed 500 treatment courses (TCs) from the ANSWER cohort in which subsequent b/tsDMARDs were initiated after JAKi discontinuation. Subsequent treatments were classified as TNF inhibitors (TNFi), anti-IL-6 receptor antibodies (aIL-6R), CTLA4-Ig and JAKi. Drug retention was stratified by the reason for prior JAKi discontinuation and evaluated using Kaplan-Meier and multivariable Cox analyses. Changes in Clinical Disease Activity Index (CDAI) over 12 months were analysed using mixed-effects models for repeated measures. Results After prior JAKi discontinuation due to ineffectiveness, CTLA4-Ig was associated with a significantly higher risk of discontinuation due to ineffectiveness than subsequent JAKi (HR 2.83, 95% CI 1.20–6.70). Among TCs in which the prior JAKi was discontinued due to toxic adverse events (AEs), TNFi and aIL-6R were associated with lower risks of toxic AE-related discontinuation than JAKi. Overall CTLA4-Ig was associated with higher risks of discontinuation due to ineffectiveness (HR 2.57, 95% CI 1.46–4.54) and total discontinuation excluding non-toxic reasons and remission (HR 1.77, 95% CI 1.02–3.07). CDAI trajectories over 12 months did not differ significantly between treatment groups. Conclusion The optimal treatment strategy after JAKi discontinuation may depend on the reason for prior discontinuation. JAKi cycling, TNFi and aIL-6R may be reasonable after ineffectiveness, whereas after toxic AEs, TNFi and aIL-6R were associated with lower risks of subsequent toxic AE-related discontinuation than JAKi cycling.
Reference Key
openalex_W7223035603 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yuhei Fujisawa, Ryu Watanabe, Yuya Yano, Kosaku Murakami, Koichi Murata, Yuri Hiramatsu, Toru Takeuchi, Yuki Etani, Yasutaka Okita, Hideki Amuro, Hirotaka Yamada, Yo Ueda, Ryota Hara, Masaki Katayama, Yuji Nozaki, Tetsu Itami, Wataru Yamamoto, Ryuhei Ishihara, Masao Katsushima, Kazuo Fukumoto, Shinsuke Yamada, Tadashi Okano, Motomu Hashimoto
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag587
URL
https://doi.org/10.1093/rheumatology/keag587
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.